Agenus Inc (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies, announced yesterday that it has named Dr Allison Jeynes-Ellis as its new director.

Jeynes-Ellis, MD, FFPM (UK) is a trained clinician with more than 25 years of senior leadership experience in the pharmaceutical industry. Presently, she serves as chief executive officer at Avillion LLP.

Previously, she led development at Wyeth, BMS, Novartis, and GSK and has secured numerous US and EU drug approvals.

Garo Armen, PhD, chairman and CEO of Agenus, said, 'As we advance towards becoming a commercial organisation, I am delighted to welcome Dr Jeynes-Ellis to our board. Allison brings significant global drug development and commercialisation experience, which includes executing on global registrational studies resulting in regulatory approvals in US and EU and advising on commercialisation and reimbursement strategies. We will benefit from Allison's considerable development, regulatory, and commercial expertise.'